EPZM Stock Recent News
EPZM LATEST HEADLINES
Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.
Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
A buyout ends Epizyme's 15-year tenure as an independent biopharma.
Ipsen SA (OTC: IPSEY) has agreed to acquire Epizyme Inc (NASDAQ: EPZM) at $1.45 per share for approximately $247 million, plus one contingent value right (CVR) per share. The deal is expected to close by Q3.
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates.
Epizyme, Inc. (NASDAQ:EPZM ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Grant Bogle – President and Chief Executive Officer Shefali Agarwal - Senior Medical Adviser, Interim Chief Medical and Development Officer Joe Beaulieu - Senior Vice President, Head of Finance Jerald Korn - Chief Operating Officer Conference Call Participants Peter Lawson - Barclays Peyton Bohnsack - Cowen Operator Hello, and welcome to Epizyme's First Quarter 2022 Financial Results Conference Call. At this time, all participants on a listen-only mode.
Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.